// App-Quantinova.ai

5453 : FCN-289, a novel, potent and selective PI3Kδ inhibitor for the treatment of B-cell malignancies

Researchers

Presenter

  • Shu Lin

Principal Investigators

  • Zuwen Zhou

  • Rui Tan

  • Hua Xu

  • Huajie Zhang

  • Weipeng Zhang

  • Ling Chen

  • Lijun Yang

  • Xingdong Zhao

  • Yanxin Liu

  • Zongyao Zou

  • Yuwei Gao

  • Jiashu Zhou

  • Weibo Wang

Medical Centers

  • Fochon Pharmaceuticals, Ltd, Chongqing, China

  • Fochon Pharma, Inc, San Leandro, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Diffuse large B-cell lymphoma

  • Chronic Lymphocytic Leukemia

  • Mucosa-associated lymphoid tissue lymphoma

  • B cell lymphomas

  • Follicular lymphoma

  • Venous thrombosis

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Bruton tyrosine kinase

  • Phosphoinositide 3-kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Idelalisib

  • Umbralisib

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved